「nov」の検索結果
20件：11～15件目を表示
-
お知らせ | 千寿製薬株式会社
5 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V m...
https://www.senju.co.jp/english/news/ -
お知らせ | 千寿製薬株式会社
5 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V m...
http://www.senju.co.jp/english/news/ -
Milestones in Our History | About Senju | SENJU Pharmaceutical
t for manufacturing established in Kanzaki-gun, Hyogo June Shoji Yoshida became the President. 1978 November Company head office relocated in Hiranomachi, Higashi-ku, Osaka. 1980 February Ophthalmic S...
https://www.senju.co.jp/english/about/history.html -
お知らせ | 千寿製薬株式会社
日 Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential cation channel subfamily V m...
http://www.senju.co.jp/chinese/news/ -
学会发表 | 研究与开发 | 千寿制药株式会社
. ARVO 2025 開催日：2025年5月4日～2025年5月8日 開催地：Salt Lake City, Utah, United States of America Effects of a novel TRPV1 antagonist, SJP-0132, on CCL5 expression in corneal epithelial cells Yuya Atsumi, Toshiz...
http://www.senju.co.jp/chinese/rd/society/